Highlights Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-02 pm EDT			5-day change	1st Jan Change
0.707 ^USD	-2.66%		-3.49%	-6.54%

Apr. 26	Citius Pharmaceuticals Launches $15 Million Offering	MT
Apr. 11	Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Citius Pharmaceuticals Launches $15 Million Offering	Apr. 26	MT
Citius Pharmaceuticals, Inc. Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma	Apr. 11	CI
Citius Pharmaceuticals, Inc. Announces FDA Acceptance of the BLA Resubmission of LYMPHIR (Denileukin Diftitox) for the Treatment of Adults with Relapsed or Refractory Cutaneous T-Cell Lymphoma	Mar. 18	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 14	CI
Citius Pharmaceuticals, Inc. Announces the Resubmission of the Biologics License Application to the U.S. Food and Drug Administration for Lymphir	Feb. 14	CI
Citius Pharmaceuticals, Inc. Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok Therapeutic to Salvage Catheters	Jan. 02	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 29	CI
North American Morning Briefing : S&P 500 Futures Dip with Fresh Record in Sight	Dec. 20	DJ
Citius Pharmaceuticals, Inc. Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR? in Combination with Checkpoint Inhibitor	23-10-31	CI
Citius Pharmaceuticals to Merge Oncology Unit with TenX Keane Acquisition; Citius Shares Rise	23-10-24	MT
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration Regarding the Planned Resubmission of the BLA for LYMPHIR	23-09-08	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-08-14	CI
Citius Pharmaceuticals, Inc. Reaches 92 Event Milestone in Mino-Lok Phase 3 Trial	23-08-10	CI
Citius Pharmaceuticals Says FDA Requests Enhanced Product Testing, More Controls for Cutaneous T-Cell Lymphoma Therapy	23-07-31	MT
Citius Pharmaceuticals, Inc. Receives a Complete Response Letter from the U.S. Food and Drug Administration for LYMPHIR? (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma	23-07-29	CI
Citius Pharmaceuticals, Inc. Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids	23-06-20	CI
Citius Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-05-12	CI
Citius Pharmaceuticals Advances Mino-Lok® Phase 3 Trial Achieving 85 of 92 Events to Date	23-04-24	CI
Citius Pharmaceuticals, Inc. Completes Enrollment in Phase 2b Study of Halo-Lido for the Prescription Treatment of Hemorrhoids	23-04-03	CI
Citius Pharmaceuticals Engages Financial Advisor for Oncology Subsidiary Spinoff	23-03-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Citius Pharmaceuticals, Inc.

Equities

CTXR

US17322U2078

Highlights

Filters